Medicines Optimisation

Phyllocontin® (aminophylline) Continus 225mg and Phyllocontin® Forte Continus 350mg modified-release tablets are being discontinued in the UK. Remaining supplies of the 225mg strength are expected to be exhausted by 2nd March 2021 and the 350mg strength are expected to be exhausted by 5th April 2021. All healthcare professionals in primary, secondary and specialist healthcare services …

Read more

Pregabalin has been associated with reports of respiratory depression, in some cases without concomitant opioid treatment.Healthcare professionals are advised to consider whether adjustments in dose or dosing regimen are necessary for patients at higher risk of respiratorydepression, this includes people: with compromised respiratory function, respiratory or neurological disease, orrenal impairment taking other CNS depressants (including …

Read more

MHRA Drug Safety Update: Alkindi (hydrocortisone granules): Risk of adrenal insufficiency when switching formulations. When children receiving replacement therapy for adrenal insufficiency are beingswitched from hydrocortisone tablets to Alkindi granules, parents or carers should be informed of the need to be extra vigilant for symptoms of adrenal insufficiency.Advice for healthcare professional is: Adrenal crisis has …

Read more

Colchicine should not be used in the management of COVID-19 within primary care, other than in the context of a trial. Use in licensed indications remains unaffected.Subject to regulatory approval, agreement has been reached to add colchicine to the PRINCIPLE trial. Practices are encouraged to continue to support recruitment to this important UK platform trial, …

Read more

News about Covid-19 vaccine training for practice staff More information follows here Text here about vaccine for coronavirus Information about staff training Vaccination programme